This is not a guarantee, and deep discounts should still be evaluated against quality evidence
the time intervals for the study were as follows: 0.5hr, lhr, 2hr, 4hr, 6hr, 8hr, lOhr, l2hr, 24hr after application of a patch
Moreover, in light of the growing evidence demonstrating the benefits of incretin-based therapies on both metabolic health and cardiovascular diseases, regulatory agencies such as the Food Drug Administration (FDA) and the European Medicines Agency (EMA) have approved their use for type 2 diabetes, reduction of cardiovascular risk and for chronic weight management in patients with morbid obesity [5,6,7,8]
Acknowledgements: The authors thank Steven Lamberti, MD, for his critical advice and review of the manuscript